We expect Novo to gain $75 billion of a more than $200 billion global GLP-1 market in diabetes and obesity by 2031, ahead of semaglutide's 2032 patent expiration, with Lilly standing as the firm's key ...

Novo Nordisk today announced 2024 earnings, reporting a 26% increase in annual sales to ~$40.56bn. Read why I upgrade NVO ...

A settlement with drug-maker Novo Nordisk resolves the state's years-long litigation over insulin pricing and follows similar settlements already reached with Eli Lilly and Sanofi. “In 2018 ...

Novo Nordisk A/S NVO reported fourth-quarter 2024 earnings of 91 cents per American Depositary Receipt (ADR), which beat the ...

It turns out that the anti-obesity space isn't growing as fast as Eli Lilly or analysts anticipated, resulting in ...

Studies have suggested that GLP-1RAs may show promise for a host of conditions, from alcohol use disorder to Parkinson’s. But ...

and fast-acting insulin Humalog. And that's before we get into the company's pipeline, which features plenty of investigational drugs beyond Eli Lilly's core area of diabetes and obesity.

Eli Lilly’s big-selling insulin, Humalog, faces cut-price competition after the US regulator approved a biosimilar from Sanofi. Sanofi’s Admelog (insulin lispro) is approved in type 1 and type ...

Detailed price information for Lexaria Bioscience Corp (LEXX-Q) from The Globe and Mail including charting and trades.

KELOWNA, BC / ACCESS Newswire / January 30, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW), (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to provi ...